Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

PSTX

Poseida Therapeutics Inc

Jan 07 • 04:00PM ET

9.50

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP BMRN NTLA BLUE EDIT RGNX QURE SGMO VYGR ADVM

| Held by: VTI VXF VTWO VTWV DFAS VTWG XDNA DFAC DFAU DFUS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.63	Insider Own	30.84%	Shs Outstand	97.41M	Perf Week	0.21%
Market Cap	925.97M	Forward P/E	-	EPS next Y	-1.72	Insider Trans	-0.20%	Shs Float	69.15M	Perf Month	1.82%
Income	-60.76M	PEG	-	EPS next Q	-0.50	Inst Own	55.83%	Short Float	5.19%	Perf Quarter	257.14%
Sales	150.86M	P/S	6.14	EPS this Y	44.53%	Inst Trans	7.18%	Short Ratio	2.14	Perf Half Y	219.87%
Book/sh	0.90	P/B	10.61	EPS next Y	-125.66%	ROA	-20.39%	Short Interest	3.59M	Perf Year	199.68%
Cash/sh	2.37	P/C	4.01	EPS next 5Y	-	ROE	-57.63%	52W Range	1.87 - 9.67	Perf YTD	-1.04%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-12.83%	ROI	-37.08%	52W High	-1.76%	Beta	1.63
Dividend TTM	-	Quick Ratio	3.20	Sales past 5Y	66.83%	Gross Margin	96.38%	52W Low	408.02%	ATR (14)	0.20
Dividend Ex-Date	-	Current Ratio	3.20	EPS Y/Y TTM	57.79%	Oper. Margin	-41.43%	RSI (14)	75.33	Volatility	1.67% 1.16%
Employees	330	Debt/Eq	0.95	Sales Y/Y TTM	203.18%	Profit Margin	-40.28%	Recom	3.00	Target Price	9.00
Option/Short	Yes / No	LT Debt/Eq	0.88	EPS Q/Q	160.24%	Payout	-	Rel Volume	0.00	Prev Close	9.50
Sales Surprise	341.53%	EPS Surprise	150.30%	Sales Q/Q	667.19%	Earnings	Nov 07 AMC	Avg Volume	1.67M	Price	9.50
SMA20	0.17%	SMA50	45.66%	SMA200	150.82%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-24	Downgrade	Piper Sandler	Overweight → Neutral	$10
Jan-04-23	Initiated	H.C. Wainwright	Buy	$15
Jan-07-22	Initiated	Cantor Fitzgerald	Overweight	$24
May-18-21	Initiated	BTIG Research	Buy	$40
Aug-04-20	Initiated	William Blair	Outperform
Aug-04-20	Initiated	Piper Sandler	Overweight	$30
Aug-04-20	Initiated	BofA Securities	Buy	$20

Jan-08-25 01:35AM	Roche to complete $1.5 billion acquisition of U.S. biopharma company Poseida (Reuters)
01:10AM	Roche purchases shares in tender offer for Poseida Therapeutics, Inc. (GlobeNewswire)
Dec-13-24 09:15AM	Poseida Therapeutics, Inc. (PSTX) Hits Fresh High: Is There Still Room to Run? (Zacks)
Dec-09-24 04:30PM	Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash (GlobeNewswire)
12:00PM	Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting (PR Newswire)
06:33PM	Loading…
Dec-06-24 06:33PM	PBF Energy, Poseida Therapeutics, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-28-24 09:55AM	Should You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross? (Zacks)
Nov-27-24 09:55AM	Wall Street Analysts Think Poseida Therapeutics (PSTX) Could Surge 49.25%: Read This Before Placing a Bet (Zacks)
09:15AM	Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue? (Zacks)
06:50AM	Poseida Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald (TipRanks)
Nov-26-24 11:10AM	Why This Gene-Therapy Companys Stock Is Rising 228% (Barrons.com) +227.97%
09:07AM	Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details (Benzinga)
06:19AM	Roche to acquire Poseida Therapeutics for $1.5bn (Pharmaceutical Technology)
05:47AM	Roche to buy cell therapy developer Poseida for $1B (BioPharma Dive)
03:54AM	Roche to Acquire Poseida Therapeutics in a Deal Worth Up to $1.5 Billion (The Wall Street Journal)
01:28AM	Loading…
01:28AM	Roche to acquire cell therapy maker Poseida Therapeutics in $1.5 billion deal (Reuters)
01:10AM	Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies (GlobeNewswire)
01:10AM	Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc. (PR Newswire)
Nov-14-24 09:00AM	Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline (PR Newswire)
Nov-12-24 12:00PM	Poseida Therapeutics, Inc. (PSTX) Is Up 24.70% in One Week: What You Should Know (Zacks)
Nov-11-24 04:05PM	Poseida Therapeutics to Present at Two Upcoming Investor Conferences (PR Newswire) +20.45%
Nov-07-24 05:55PM	Poseida Therapeutics, Inc. (PSTX) Q3 Earnings and Revenues Beat Estimates (Zacks) +5.40% +5.12%
04:05PM	Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024 (PR Newswire)
Nov-05-24 04:05PM	Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024 (PR Newswire) +5.14%
Oct-24-24 08:00AM	Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema (PR Newswire)
Oct-17-24 08:00AM	Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche (PR Newswire)
Oct-15-24 08:05AM	MaxCyte Appoints Cynthia Collins to its Board of Directors (GlobeNewswire)
Oct-03-24 04:30PM	Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024 (PR Newswire)
Sep-27-24 04:30PM	Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients (PR Newswire)
Sep-17-24 04:12AM	FDA grants RMAT to Poseidas CAR-T cell therapy P-BCMA-ALLO1 (Pharmaceutical Technology) +12.67%
08:00AM	Loading…
Sep-16-24 08:00AM	Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma (PR Newswire)
Sep-05-24 09:00AM	Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting (PR Newswire)
Sep-04-24 04:05PM	Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma (PR Newswire)
Aug-29-24 04:05PM	Poseida Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
Aug-05-24 09:55PM	PSTX Stock Earnings: Poseida Therapeutics Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:55PM	Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024 (PR Newswire)
Jul-19-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Poseida Therapeutics, Inc. (PSTX) is a Great Choice (Zacks) -5.26%
Jul-01-24 04:05PM	Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum (PR Newswire)
Jun-03-24 04:05PM	Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders (PR Newswire) -13.40%
May-14-24 09:53PM	PSTX Stock Earnings: Poseida Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +18.49%
05:08PM	Poseida Therapeutics Q1 Net Loss Narrows, Revenue Rises (MT Newswires)
04:05PM	Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 (PR Newswire)
May-09-24 09:00AM	Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting (PR Newswire)
May-02-24 06:22AM	Xyphos and Poseida to develop allogeneic cell therapies for cancer (Pharmaceutical Technology)
06:04AM	Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos (MT Newswires)
May-01-24 09:30PM	Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology (PR Newswire) +14.46%
05:42AM	Astellas adds to off-the-shelf cell therapy capabilities with Poseida deal (BioPharma Dive)
Apr-18-24 08:00AM	Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting (PR Newswire)
Apr-17-24 09:00AM	Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus (PR Newswire)
Apr-08-24 12:00PM	Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma (PR Newswire)
Apr-01-24 04:05PM	Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.45%
Mar-25-24 04:05PM	Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer (PR Newswire) -7.57%
Mar-19-24 04:05PM	Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (PR Newswire)
Mar-13-24 04:05PM	Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma (PR Newswire) +7.57%
Mar-07-24 10:53PM	PSTX Stock Earnings: Poseida Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) +18.66%
10:45PM	Poseida Therapeutics Inc (PSTX) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
06:55PM	Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:07PM	Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023 (PR Newswire)
Mar-04-24 04:05PM	Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -10.77% -5.56%
Jan-04-24 08:00AM	Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones (PR Newswire)
Dec-10-23 12:00PM	Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting (PR Newswire)
Nov-17-23 01:08PM	Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare (InvestorPlace) +5.58%
Nov-09-23 04:05PM	Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023 (PR Newswire)
Nov-07-23 08:00AM	Poseida Therapeutics to Present at Two Upcoming Investor Conferences (PR Newswire)
Nov-02-23 10:00AM	Poseida Therapeutics, Inc. (PSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) +5.31%
09:01AM	Poseida Therapeutics to Present at the 65th ASH Annual Meeting and Exposition (PR Newswire)
Oct-16-23 12:00PM	All You Need to Know About Poseida Therapeutics, Inc. (PSTX) Rating Upgrade to Buy (Zacks) +6.41%
Oct-09-23 04:30PM	Poseida Therapeutics Announces Leadership Transition (PR Newswire)
Oct-03-23 05:00PM	Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich (InvestorPlace)
Sep-05-23 08:00AM	Poseida Therapeutics to Present at Two Upcoming Investor Conferences (PR Newswire)
Aug-10-23 06:02AM	News Flash: Analysts Just Made An Upgrade To Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Forecasts (Simply Wall St.)
Aug-08-23 05:40PM	Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +37.88%
04:05PM	Poseida Therapeutics Provides Financial Results for the Second Quarter of 2023 (PR Newswire)
Aug-07-23 09:01AM	Poseida Therapeutics Announces Strategic Investment by Astellas and Provides Business Update (PR Newswire) +21.47%
09:00AM	Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy (PR Newswire)
Jul-31-23 08:23AM	The past three years for Poseida Therapeutics (NASDAQ:PSTX) investors has not been profitable (Simply Wall St.)
Jul-05-23 08:00AM	Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell Malignancies (PR Newswire)
Jun-26-23 08:00AM	Poseida Therapeutics to Join Russell 3000® and Russell 2000® Indexes (PR Newswire) -11.06%
Jun-01-23 08:00AM	Poseida Therapeutics Announces Virtual 2023 Annual Meeting of Stockholders (PR Newswire)
May-23-23 08:00AM	Poseida Therapeutics to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day (PR Newswire)
May-22-23 08:00AM	Poseida Therapeutics to Present at 31st Congress of the International Society on Thrombosis and Haemostasis (PR Newswire) +9.30%
May-18-23 08:00AM	Poseida Therapeutics Presents Encouraging Preclinical Data Across its Gene Therapy Programs at the American Society for Gene and Cell Therapy 2023 Annual Meeting (PR Newswire) -6.67%
May-11-23 06:11AM	Poseida Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.) -9.00%
May-10-23 12:00PM	What Makes Poseida Therapeutics, Inc. (PSTX) a New Buy Stock (Zacks)
May-09-23 07:05PM	Poseida Therapeutics, Inc. (PSTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2023 (PR Newswire)
May-02-23 04:30PM	Poseida Therapeutics Announces Multiple Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting (PR Newswire)
May-01-23 08:00AM	Poseida Therapeutics to Present at BofA Securities 2023 Health Care Conference (PR Newswire)
Apr-17-23 06:48AM	Benign Growth For Poseida Therapeutics, Inc. (NASDAQ:PSTX) Underpins Stock's 44% Plummet (Simply Wall St.)
Apr-13-23 08:00AM	Poseida Therapeutics Appoints Rafael G. Amado, M.D., to Board of Directors (PR Newswire)
Apr-11-23 04:05PM	Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.73%
08:00AM	Poseida Therapeutics Appoints Kristin Yarema, Ph.D., as President, Cell Therapy (PR Newswire)
Apr-03-23 07:09AM	With 46% stake, Poseida Therapeutics, Inc. (NASDAQ:PSTX) seems to have captured institutional investors' interest (Simply Wall St.)
Mar-09-23 06:05PM	Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -7.17% -18.81%
04:05PM	Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2022 (PR Newswire)
Mar-01-23 08:00AM	Poseida Therapeutics Appoints Five New Members to Its Gene Therapy Scientific Advisory Board (PR Newswire) -5.98%
Feb-22-23 08:00AM	Poseida Therapeutics Hosts Third Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations (PR Newswire)
Feb-21-23 06:50AM	Poseida Therapeutics (NASDAQ:PSTX) shareholders are still up 91% over 1 year despite pulling back 10.0% in the past week (Simply Wall St.)
Feb-15-23 08:50AM	Here's What Could Help Poseida Therapeutics, Inc. (PSTX) Maintain Its Recent Price Strength (Zacks) -8.05%

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gergen Mark J	Executive Chairman	Dec 10 '24	Option Exercise	2.78	30,000	83,430	681,291	Dec 11 05:17 PM
Gergen Mark J	Executive Chairman	Dec 10 '24	Sale	9.46	30,000	283,866	651,291	Dec 11 05:17 PM
Gergen Mark J	Executive Chairman	Nov 26 '24	Option Exercise	2.78	30,000	83,430	681,291	Nov 27 07:39 PM
Gergen Mark J	Executive Chairman	Nov 26 '24	Sale	9.27	30,000	278,100	651,291	Nov 27 07:39 PM
MARK GERGEN	Director	Nov 26 '24	Proposed Sale	2.86	120,000	343,200		Nov 26 04:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PSTX

Poseida Therapeutics Inc

Upgrade your FINVIZ experience